Know What's Happening in BioTech

Microalgae Could Fuel Hawaiʻi's Renewable Future
NewsJan 5, 2026

Microalgae Could Fuel Hawaiʻi's Renewable Future

Researchers at the University of Hawaiʻi at Mānoa have demonstrated how synthetic biology and CRISPR‑based metabolic engineering can boost microalgae’s production of lipids and terpenoids, key feedstocks for renewable jet fuel, bio‑based chemicals, and pharmaceuticals. The study, published in Plant...

By Phys.org – Biotechnology
Making Smart Decisions and Investments in Trained Staff Key to 2026 Success
NewsJan 5, 2026

Making Smart Decisions and Investments in Trained Staff Key to 2026 Success

Raj Puri, chief commercial officer of Argonaut Manufacturing, warns that U.S. tariffs will keep pressuring pharma manufacturers in 2026, extending costs and timelines for new or upgraded facilities. He highlights that large capital projects face uncertainty in a volatile geopolitical...

By Pharmaceutical Technology
Quick Execution with Operational Integrity
NewsJan 5, 2026

Quick Execution with Operational Integrity

Meri Beckwith, Co‑CEO of Lindus Health, outlines how 2025 trends will shape pharma in 2026. AI moved from experimental to strategic, accelerating trial design, site selection and patient matching. Decentralized trial models combined with real‑world data enable nationwide recruitment and...

By Pharmaceutical Technology
FUJIFILM Irvine Scientific Becomes FUJIFILM Biosciences
NewsJan 5, 2026

FUJIFILM Irvine Scientific Becomes FUJIFILM Biosciences

FUJIFILM Irvine Scientific rebranded as FUJIFILM Biosciences on Jan. 1, 2026, aligning its name with a 55‑year legacy in cell‑culture media and bioprocessing. The change underscores the unit’s shift toward biologics manufacturing and CDMO services. Recent strategic moves include a $3 billion, 10‑year...

By Pharmaceutical Technology
Advancing Pharmaceutical Quality Through Integrated Digital Systems and Collaborative Scientific Innovation
NewsJan 5, 2026

Advancing Pharmaceutical Quality Through Integrated Digital Systems and Collaborative Scientific Innovation

Saharsh Davuluri of Neuland Labs outlines a digital overhaul of API manufacturing, leveraging AI tools such as Merck’s Synthia and automated parallel synthesizers to design scalable processes. He envisions a fully paperless plant where electronic batch records feed directly into...

By Pharmaceutical Technology
Multi-Compendial Compliance for Pharmaceutical Excipients–Part 2: A Detailed Assessment for Specification Equivalence
NewsJan 5, 2026

Multi-Compendial Compliance for Pharmaceutical Excipients–Part 2: A Detailed Assessment for Specification Equivalence

The article presents a technical assessment of compendial tests across the European Pharmacopoeia, USP‑NF, and Japanese Pharmacopoeia to establish specification equivalence for pharmaceutical excipients. It recommends standardizing on the Ph. Eur. method for most tests, applying the tightest acceptance criteria, and...

By Pharmaceutical Technology
Nearly Every Corn Seed Planted in Colorado Is Covered in Insecticide: Lawmakers May Restrict the Chemical
NewsJan 5, 2026

Nearly Every Corn Seed Planted in Colorado Is Covered in Insecticide: Lawmakers May Restrict the Chemical

Nearly every corn seed planted in Colorado is coated with a neonicotinoid insecticide, a practice that protects seedlings but also introduces the chemical into plants, soil and water. Environmental groups are drafting legislation that would ban such coatings unless farmers...

By Phys.org – Biotechnology
Machine Learning Drives Drug Repurposing for Neuroblastoma
NewsJan 5, 2026

Machine Learning Drives Drug Repurposing for Neuroblastoma

Researchers at Lund University used machine learning to repurpose existing drugs for high‑risk neuroblastoma. They identified a synergistic combination of a statin and a phenothiazine that markedly slowed tumor growth in mouse models. Laboratory trials showed reduced tumor cholesterol, increased...

By World Pharma News
RO4938581, a GABAA-Α5 Negative Allosteric Modulator Rescued Behavioral and EEG Phenotypes of a Mouse Model of Dup15q Syndrome
NewsJan 5, 2026

RO4938581, a GABAA-Α5 Negative Allosteric Modulator Rescued Behavioral and EEG Phenotypes of a Mouse Model of Dup15q Syndrome

The study shows that mice carrying the 15q duplication exhibit ~1.5‑fold elevation of GABA A‑α5 receptors in cortex, hippocampus and striatum, leading to heightened inhibitory synaptic activity and a characteristic increase in beta‑band EEG power. Chronic oral administration of the selective...

By Nature (Biotechnology)
Weekly Reads: The Stem Cell Niche, Tongue Stem Cells, Autoimmune Diseases
BlogJan 4, 2026

Weekly Reads: The Stem Cell Niche, Tongue Stem Cells, Autoimmune Diseases

The post highlights recent advances in stem cell niche research, focusing on bone‑marrow organoid models, niche‑preserving intestinal transplants, and the discovery of tripotent Lgr5+ stem cells in the posterior tongue that generate lingual, taste, and salivary lineages. It curates related...

By The Niche
A Better Way to Detect Off-Target Genome Changes From Base Editors
NewsJan 3, 2026

A Better Way to Detect Off-Target Genome Changes From Base Editors

St. Jude Children’s Research Hospital unveiled CHANGE‑seq‑BE, a new assay that sensitively maps off‑target activity of CRISPR base editors while using only a fraction of sequencing resources. The method, published in Nature Biotechnology, demonstrated 95.4 % on‑target specificity in an FDA‑emergency case...

By Phys.org – Biotechnology
Epigenetic Mechanisms Affected by Stress During Adolescence and the Increased Risk for Depression Later in Life: A Systematic Review
NewsJan 3, 2026

Epigenetic Mechanisms Affected by Stress During Adolescence and the Increased Risk for Depression Later in Life: A Systematic Review

This systematic review examined how stressful life events during adolescence reshape epigenetic landscapes and elevate depression risk later in life. By screening 30 preclinical and clinical studies, the authors identified consistent DNA methylation and micro‑RNA changes—particularly affecting the BDNF pathway—in...

By Nature (Biotechnology)
Harmeier Returns to Lead Roche Venture Fund
NewsJan 2, 2026

Harmeier Returns to Lead Roche Venture Fund

Roche has announced that Dr. Harmeier is returning to head its Roche Venture Fund, the pharma giant’s dedicated early‑stage investment arm. Harmeier previously led the fund from 2015 to 2020 before moving to a senior role within Roche’s corporate development...

By BioCentury
Insilico’s Big Gain After Hong Kong Listing: Finance Report
NewsJan 2, 2026

Insilico’s Big Gain After Hong Kong Listing: Finance Report

Insilico Medicine saw its stock surge after debuting on the Hong Kong Stock Exchange, climbing roughly 45% on the first trading day. The secondary offering raised about $1.2 billion, pushing the company’s market capitalization past the $10 billion mark. The strong demand...

By BioCentury
Best of BioCentury 2025
NewsJan 2, 2026

Best of BioCentury 2025

BioCentury released its "Best of BioCentury 2025" collection, curating the year’s most consequential biotech stories from its editorial team. The anthology spotlights breakthroughs in gene‑editing, AI‑driven drug discovery, and evolving regulatory frameworks. By distilling these seminal moments, BioCentury reinforces its mission...

By BioCentury
Advocates Regroup After Sanders Blocks Pediatric PRV Reauthorization
NewsJan 2, 2026

Advocates Regroup After Sanders Blocks Pediatric PRV Reauthorization

Senator Bernie Sanders halted a Senate vote to reauthorize the rare pediatric disease priority review voucher (PRV) program, demanding unrelated multi‑billion‑dollar spending measures be adopted first. Although he expressed support for the PRV incentive, Sanders made clear his conditions would...

By BioCentury
Industry Outlook 2026: Success Through Top Talent, AI Utilization, and Sustainability
NewsJan 2, 2026

Industry Outlook 2026: Success Through Top Talent, AI Utilization, and Sustainability

Ardena US managing director Ian Bilodeau says AI is reshaping pharma by linking fragmented data and speeding product decisions. He also emphasizes that attracting and developing top talent requires challenging, impact‑focused work environments. Sustainability, highlighted by Ardena’s EcoVadis certification, is...

By Pharmaceutical Technology
The Evolution of Data-First Regulatory Operations
NewsJan 2, 2026

The Evolution of Data-First Regulatory Operations

Remco Munnik of Arcana Life Sciences says European regulators are cementing a data‑first approach, with the EMA’s electronic product database and digital submission forms becoming standard. The pharma sector is eager to embed AI for document automation and quality oversight,...

By Pharmaceutical Technology
Grading My 25 Stem Cell & Regenerative Medicine Predictions for 2025
BlogJan 2, 2026

Grading My 25 Stem Cell & Regenerative Medicine Predictions for 2025

The author graded 25 2025 predictions for stem cell and regenerative medicine, finding most were accurate despite some disappointing headlines. Key highlights include reduced FDA oversight paired with notable warnings in the perinatal space, a successful Mesoblast approval, and several...

By The Niche
Zoliflodacin (ETX-0914)
BlogJan 2, 2026

Zoliflodacin (ETX-0914)

Zoliflodacin (ETX-0914) received FDA approval as an oral bacterial type II topoisomerase inhibitor for the treatment of urogenital gonorrhea. The drug emerged from rational design of earlier inhibitors and is the product of a partnership among AstraZeneca, Entasis, Innoviva and GARDP....

By Drug Hunter
Double Cone Tumble Blender Provides Homogeneity in Heavy-Duty Applications
NewsJan 2, 2026

Double Cone Tumble Blender Provides Homogeneity in Heavy-Duty Applications

Charles Ross & Son introduced the DCB-5 Double Cone Tumble Blender, a five‑cubic‑foot unit designed for high‑density powder processing. The machine combines a stainless‑steel jacket, a 2 HP intensifier bar, and an integrated vacuum system to deliver repeatable homogeneity and simultaneous...

By Pharmaceutical Technology
A Zero-Shot Learning Framework for Maize Cob Phenotyping
NewsJan 2, 2026

A Zero-Shot Learning Framework for Maize Cob Phenotyping

Scientists have unveiled a zero‑shot learning framework that phenotypes maize cob geometry without any model retraining. The system combines text‑guided object detection, lightweight segmentation, and calibrated trait extraction, delivering 98‑100% detection accuracy and over 0.95 correlation for trait estimates. It...

By Phys.org – Biotechnology
From AI to Smart Factories: How Pharma Is Preparing for 2026
NewsJan 2, 2026

From AI to Smart Factories: How Pharma Is Preparing for 2026

Manish Garg of Hikma Pharmaceuticals highlighted how AI, personalized medicine, and smart manufacturing reshaped pharma in 2025 and set the agenda for 2026. AI accelerated drug discovery and clinical design, while niche, high‑value therapies gained prominence. Companies are regionalizing supply...

By Pharmaceutical Technology
New Technique Lights up Where Drugs Go in the Body, Cell by Cell
NewsJan 2, 2026

New Technique Lights up Where Drugs Go in the Body, Cell by Cell

Researchers at Scripps have unveiled vCATCH, a whole‑body imaging platform that lights up covalent drugs at single‑cell resolution in mice. By attaching a tiny chemical handle to drugs and using highly selective click‑chemistry, the method tags each bound molecule with...

By World Pharma News
HITL and HOTL: An Air Traffic Control Analogy for Agentic AI
NewsJan 1, 2026

HITL and HOTL: An Air Traffic Control Analogy for Agentic AI

ArisGlobal’s senior VP Jason Bryant argues that both human‑in‑the‑loop (HITL) and human‑on‑the‑loop (HOTL) remain essential for deploying agentic AI in pharma. He uses an air‑traffic‑control analogy, portraying AI agents as aircraft and the orchestration layer as air‑traffic management. Bryant stresses...

By Pharmaceutical Technology
Pain‑free Surgery Once Seemed Impossible, Now It's Reality
SocialDec 31, 2025

Pain‑free Surgery Once Seemed Impossible, Now It's Reality

If restoring youthful function in old tissues sounds radical, remember that surgery without pain once did to

By David Sinclair
Legends Lost: Baltimore, Rutter Among Biotech’s Greats to Depart in 2025
NewsDec 31, 2025

Legends Lost: Baltimore, Rutter Among Biotech’s Greats to Depart in 2025

The biotech community mourned the loss of several iconic figures in 2025, including Nobel laureate David Baltimore and industry pioneer Rutter. Their careers spanned groundbreaking scientific discoveries, the founding of biotech firms, and the cultivation of global research ecosystems. The...

By BioCentury
Industry Outlook 2026: The Impact of Novel Therapies
NewsDec 30, 2025

Industry Outlook 2026: The Impact of Novel Therapies

In 2025 the pharmaceutical sector saw a surge of novel therapies, notably next‑generation biologics such as bispecifics, fusion proteins, multi‑specifics, and a wave of antibody‑drug conjugates (ADCs). A breakthrough sub‑category, antibody‑oligo conjugates (AOCs), gained traction for muscular dystrophy, highlighted by...

By Pharmaceutical Technology
Sanofi Adds HBV Vaccine, Shingles Candidate via Dynavax Takeout: Deals Report
NewsDec 30, 2025

Sanofi Adds HBV Vaccine, Shingles Candidate via Dynavax Takeout: Deals Report

Sanofi has agreed to acquire two vaccine assets from Dynavax, including an approved hepatitis B vaccine and a late‑stage shingles candidate. The transaction, announced in late December 2025, adds to Sanofi’s existing vaccine portfolio and broadens its reach in both...

By BioCentury
Colossal Biosciences Wins 2025 The Screamers Award for Science Hype on Dire Wolf De-Extinction Claim
BlogDec 30, 2025

Colossal Biosciences Wins 2025 The Screamers Award for Science Hype on Dire Wolf De-Extinction Claim

Colossal Biosciences was awarded the 2025 The Screamers Award for its overstated claim of de‑extincting the dire wolf. In reality the firm only introduced a handful of dire‑wolf‑related gene edits into existing gray wolves, leaving the animals genetically gray wolves....

By The Niche
Right Blood Pressure Drug Can Reduce Healthcare Costs
NewsDec 30, 2025

Right Blood Pressure Drug Can Reduce Healthcare Costs

Researchers analyzed over 340,000 Swedish hypertension patients and found that initiating treatment with angiotensin‑receptor blockers (ARBs) leads to markedly higher long‑term medication persistence. After five years, 80 % of ARB starters remained adherent, versus 65 % for calcium‑channel blockers, the next best...

By World Pharma News
AI-Driven Breeding Strategy Aims to Boost Orphan Crops for Food Security
NewsDec 30, 2025

AI-Driven Breeding Strategy Aims to Boost Orphan Crops for Food Security

A team led by Prof. Xu Cao at the Chinese Academy of Sciences has proposed an AI‑empowered breeding framework, dubbed DSAP, to accelerate the domestication of orphan crops such as fonio, tef, and cowpea. The strategy integrates de novo genome editing,...

By Phys.org – Biotechnology
BioCentury’s 2025-26 Picks and Predictions. Plus: BioMarin and More Biotech ICYMI — a BioCentury Podcast
NewsDec 30, 2025

BioCentury’s 2025-26 Picks and Predictions. Plus: BioMarin and More Biotech ICYMI — a BioCentury Podcast

BioCentury’s year‑end podcast highlights 2025 as a turning point for biotech, with revived market sentiment, robust M&A activity and a more assertive FDA under new leadership. Analysts spotlight the $4.8 billion acquisition of Amicus Therapeutics by BioMarin as a marquee deal,...

By BioCentury
2025 Was an Inflection Point. Will 2026 Show the Impact?
NewsDec 30, 2025

2025 Was an Inflection Point. Will 2026 Show the Impact?

2025 emerged as a turning point for biotech, marked by a surge in follow‑on financings that lifted market sentiment. Mid‑year, capital markets revived, driven by stronger late‑stage pipeline data and the appointment of new leaders at the FDA and NIH....

By BioCentury
Bone Disease Readout Sinks Mereo, Ultragenyx Shares: Clinical Roundup
NewsDec 29, 2025

Bone Disease Readout Sinks Mereo, Ultragenyx Shares: Clinical Roundup

Mereo BioPharma and Ultragenyx reported disappointing readouts from their bone disease programs, triggering sharp declines in both stocks. Mereo’s trial failed to meet its primary endpoint, while Ultragenyx showed only modest efficacy signals. The market reaction erased roughly 15% of...

By BioCentury
From One Voice to Many: Gabriella Rubert, Riley Conover Elmer & Karishma Chhugani
PodcastDec 29, 202530 min

From One Voice to Many: Gabriella Rubert, Riley Conover Elmer & Karishma Chhugani

Gabriella Rubert reflects on her tenure as host of the Inside Biotech podcast, discussing the challenges of translating complex science into engaging stories and the responsibility that comes with science communication. She emphasizes the power of storytelling to bridge biotech...

By Inside Biotech
Review of 2025 Reviews
BlogDec 29, 2025

Review of 2025 Reviews

The Practical Fragments blog celebrated its thousandth post in 2025, highlighting a decade of fragment‑based drug discovery (FBDD) milestones. Key reviews covered fragment‑to‑lead successes, the rise of covalent fragments, AI‑driven cryptic pocket discovery, and extensive bibliometric analysis showing steady global...

By Practical Fragments
Full Autonomy Is a ‘No-Go Zone’: Setting Parameters for Agentic AI in Pharma
NewsDec 29, 2025

Full Autonomy Is a ‘No-Go Zone’: Setting Parameters for Agentic AI in Pharma

ArisGlobal senior VP Jason Bryant explains that full autonomy for AI agents is off‑limits in pharmacovigilance, citing ethical and legal concerns. Instead, he advocates bounded autonomy managed by an orchestrator that can hand control to humans when needed. The discussion...

By Pharmaceutical Technology
Top 5 Stem Cell Good News Stories of 2025
BlogDec 29, 2025

Top 5 Stem Cell Good News Stories of 2025

The 2025 stem‑cell roundup highlights five breakthrough developments: Capricor’s deramiocel for Duchenne muscular dystrophy is on track for FDA approval by 2026; three independent Parkinson’s trials reported encouraging early efficacy; Vertex’s diabetes program saw participants achieve insulin‑free periods; a Mass Brigham...

By The Niche
Top 10 Most Popular Drug Hunter Case Studies of 2025
BlogDec 29, 2025

Top 10 Most Popular Drug Hunter Case Studies of 2025

2025 proved pivotal for drug discovery, with the FDA approving 44 new therapies and several breakthrough candidates advancing to late‑stage trials. The most‑read case studies highlighted oral macrocycles, innovative PK engineering, and first‑in‑class modalities such as the pan‑RAS glue daraxonrasib...

By Drug Hunter
The Natural Human Protein Drug May Halt Neuron Death in Alzheimer's Disease
NewsDec 29, 2025

The Natural Human Protein Drug May Halt Neuron Death in Alzheimer's Disease

University of Colorado researchers found that the FDA‑approved drug sargramostim, a synthetic GM‑CSF protein, reduced the blood biomarker UCH‑L1 of neuronal death by 40% in Alzheimer’s patients, bringing levels down to those seen in early life. The study also documented...

By World Pharma News
Structural Covariance, Regional Topology, and Volumetric Aspects of Amygdala Subnuclei in Posttraumatic Stress Disorder Using Ultra-High Field Imaging
NewsDec 29, 2025

Structural Covariance, Regional Topology, and Volumetric Aspects of Amygdala Subnuclei in Posttraumatic Stress Disorder Using Ultra-High Field Imaging

Using ultra‑high‑field 7 T MRI, researchers examined amygdala subnuclei volumes, network topology, and structural covariance in 73 PTSD patients, 78 trauma‑exposed controls, and 59 non‑trauma controls. Whole‑amygdala size was unchanged, but the lateral nucleus showed opposite volume shifts: larger left lateral...

By Nature (Biotechnology)
Navigating Digitalization, QRM Maturity, and Global Compliance Convergence Into 2026
NewsDec 28, 2025

Navigating Digitalization, QRM Maturity, and Global Compliance Convergence Into 2026

Henrik Johanning of Epista Life Sciences outlines the European regulatory and manufacturing roadmap for 2026, emphasizing the operationalisation of modern quality risk management (QRM) and the need for tangible upgrades to meet EU GMP Annex 1 requirements. He highlights rising digital...

By Pharmaceutical Technology
The Top 10 PharmTech Videos of 2025
NewsDec 28, 2025

The Top 10 PharmTech Videos of 2025

The PharmTech roundup reviews the ten most‑watched videos of 2025, revealing a industry pivot toward complex modalities such as AAV‑based gene therapies, high‑concentration biologics, and radiopharmaceuticals. Across the series, manufacturers stress the "CGT 2.0" model—flexible, automated, data‑driven production—to overcome scale‑up bottlenecks....

By Pharmaceutical Technology
Researchers Develop Graphene Oxide Hybrid Electrodes for Real-Time Dopamine Monitoring
NewsDec 28, 2025

Researchers Develop Graphene Oxide Hybrid Electrodes for Real-Time Dopamine Monitoring

Researchers at SKKU, HKUST and Jeonbuk University unveiled SIDNEY, a graphene‑oxide‑wrapped hybrid electrode that enables real‑time, label‑free dopamine detection in living neurons and brain organoids. The nanostructured platform combines gold nanopillars with a thin graphene‑oxide coating, achieving a detection limit...

By Graphene-Info
Iowa AG Wins $1M From Stem Cell Clinic
BlogDec 26, 2025

Iowa AG Wins $1M From Stem Cell Clinic

An Iowa civil court awarded a $1 million judgment against Omaha Stem Cells and its owner Travis Broughton for deceptive stem‑cell therapies. The ruling also ordered reimbursement of $810,477 to 76 patients, including an additional $20,000 penalty for targeting older adults....

By The Niche
When Biotech Makes Christmas Miracles Happen — Second Edition
NewsDec 26, 2025

When Biotech Makes Christmas Miracles Happen — Second Edition

The article revisits three recent biotech breakthroughs that felt like miracles: base‑edited CAR‑T cells (BE‑CAR7) delivering remission for relapsed T‑ALL, ex vivo gene‑corrected skin grafts curing severe junctional epidermolysis bullosa, and prenatal enzyme replacement therapy mitigating infantile Pompe disease. Each case...

By Labiotech.eu
Well Dr. Stephanie Seneff, 2025 Is Over. Did Glyphosate Turn Half of All Children Autistic?
BlogDec 26, 2025

Well Dr. Stephanie Seneff, 2025 Is Over. Did Glyphosate Turn Half of All Children Autistic?

In 2014 MIT researcher Dr. Stephanie Seneff warned that glyphosate would make half of all children autistic by 2025, a claim that has now been disproven. The blog post uses this missed prediction to illustrate a broader pattern where disinformation...

By Science-Based Medicine
The Gut Bacteria that Put the Brakes on Weight Gain in Mice
NewsDec 25, 2025

The Gut Bacteria that Put the Brakes on Weight Gain in Mice

University of Utah researchers identified the gut bacterium Turicibacter as a potent modulator of metabolic health, showing it markedly reduces weight gain, blood sugar, and blood lipids in mice fed a high‑fat diet. The microbe’s effect stems from a suite...

By Phys.org – Biotechnology